Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium
December 11, 2019 18:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory...
Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium
December 04, 2019 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study
November 08, 2019 07:00 ET
|
Biothera Pharmaceuticals, Inc.
Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and...
Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced...